Instrument Inactif

Autres langues Imprimis Pharmaceuticals Inc Nasdaq

Actions

US45323A2015

Produits pharmaceutiques

Autres langues

10/08	Harrow: Q2 Earnings Snapshot
10/08	Harrow Q2 Swings to Loss, Revenue Rises
10/08	(HROW) Harrow Expects Full Year 2026 Revenue Range $350M - $365M, vs. FactSet Est of $348.5M
10/08	Earnings Flash (HROW) Harrow Posts Q2 Loss $0.46, vs. FactSet Est of $0.18 Loss
10/08	Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, vs. FactSet Est of $70.4M
10/08	Harrow Announces Second Quarter 2026 Financial Results
10/08	Harrow, Inc. Reiterates Earnings Guidance for the Full-Year 2026
10/08	Harrow, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Harrow, Inc. entered into an Asset Purchase Agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc. for $100 million.
06/08	Viatris raises annual profit forecast on branded drug strength
06/08	Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
27/07	Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
20/07	Harrow Presents Clinical Evidence Supporting Iheezo and Byooviz At Asrs 2026 Annual Meeting
20/07	Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
20/07	Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
01/07	Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
01/07	Harrow Announces Commercial Launch of BYOOVIZ In The United States
01/07	Harrow Expands Retina Portfolio With US Launch of Byooviz
01/07	Harrow Announces Commercial Launch of BYOOVIZ® in the United States
10/06	Harrow Re-Launches Verkazia Cyclosporine Ophthalmic Emulsion 0.1% for Treatment of Vernal Keratoconjunctivitis
10/06	Harrow Relaunches Verkazia for Vernal Keratoconjunctivitis
10/06	Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
27/05	Harrow to Present at William Blair’s 46th Annual Growth Stock Conference
15/05	Harrow Insider Bought Shares Worth $302,000, According to a Recent SEC Filing
13/05	HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations